Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA

NCT ID: NCT02838680

Last Updated: 2023-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-31
• Study Completion Date: 2022-10-31

Brief Summary

To evaluate the safety and performance of the HLT System in patients with severe aortic stenosis who present at high risk for aortic valve replacement surgery.

Conditions

Aortic Valve Stenosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HLT Transcatheter Aortic Valve System

Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System

Group Type: EXPERIMENTAL

HLT Transcatheter Aortic Valve System

Intervention Type: DEVICE

Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System

Interventions

HLT Transcatheter Aortic Valve System

Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. 70 years of age or older

2. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 , mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec

3. Symptomatology due to aortic stenosis resulting in one of the following:

1. NYHA Functional Classification of II or greater

2. Presence of angina

3. Presence of syncope

4. Aortic valve annular diameter ≥ 24 and ≤26 mm measured by MSCT based on area or perimeter

5. STS score of ≥8, or documented heart team agreement of high risk for surgical aortic valve replacement (SAVR) due to frailty or comorbidities.

6. Geographically available, willing to comply with follow up and able to provide written informed consent

Exclusion Criteria

1. Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success.

2. Patients at high risk for coronary obstruction in the opinion of the investigator (e.g. combination of a coronary height < 12 mm and coronary sinus diameter < 30 mm)

3. Patients with low flow/low gradient aortic stenosis

4. Patients with significant annular calcification (e.g. Agatston score > 4000)

5. Pre-existing prosthetic heart valve in any position, or prosthetic ring

6. Severe aortic, mitral or tricuspid valve regurgitation

7. Moderate to severe mitral stenosis

8. Myocardial infarction within the past 30 days*

9. Echocardiographic evidence of intracardiac mass, thrombus or vegetation

10. LVEF < 30%

11. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure

12. Hemodynamic instability requiring inotropic drug therapy within the past 14 days

13. Untreated clinically significant coronary artery disease requiring revascularization

14. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery

15. Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy

16. Patient ineligible for or refuses blood transfusions

17. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or vessels < 6 mm) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT

18. Active peptic ulcer or gastrointestinal bleeding within the past 90 days*

19. Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 month, or treatment of carotid stenosis within past two months*

20. Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease requiring chronic dialysis

21. Active infection requiring ongoing treatment

22. Need for emergent surgery or intervention other than the investigational procedure

23. Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure except for PCI which is within 7 days of the index procedure*

24. Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated

25. Life expectancy < 1 year due to non-cardiac co-morbid conditions

26. Currently participating in any investigational drug or device studies that may confound the results of this study

27. History of any cognitive or mental health status that would interfere with study participation * At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility.

• Minimum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HLT Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Josep Rodés-Cabau, MD

Role: PRINCIPAL_INVESTIGATOR

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Harindra Wijeysundera, MD

Role: PRINCIPAL_INVESTIGATOR

Sunnybrook Health Sciences Center

Locations

Sunnybrook Health Sciences Center

Toronto, Ontario, Canada

Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval

Québec, Quebec, Canada

Countries

Canada

References

Rodes-Cabau J, Williams MR, Wijeysundera HC, Kereiakes DJ, Paradis JM, Staniloae C, Saric M, Radhakrishnan S, Wilson RF, Kubo SH. Transcatheter Aortic Valve Replacement With the HLT Meridian Valve. Circ Cardiovasc Interv. 2019 Aug;12(8):e008053. doi: 10.1161/CIRCINTERVENTIONS.119.008053. Epub 2019 Jul 31.

Reference Type: RESULT

PMID: 31362540 (View on PubMed)

Other Identifiers

HLT1502

Identifier Type: -

Identifier Source: org_study_id